Search

Your search keyword '"Hermanus, Tandile"' showing total 141 results

Search Constraints

Start Over You searched for: Author "Hermanus, Tandile" Remove constraint Author: "Hermanus, Tandile"
141 results on '"Hermanus, Tandile"'

Search Results

1. Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells

2. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

3. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

4. Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters

5. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

6. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

7. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

8. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection

9. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination

12. Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor

13. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant

15. Fc effector activity and neutralization against SARS-CoV-2 BA.4 is compromised in convalescent sera, regardless of the infecting variant

16. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape

17. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity

18. SARS-CoV-2 specific B cell memory drives improved class switching and tissue homing responses to single dose Ad26.COV2.S vaccination in previously infected recipients

19. Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial

21. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

22. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

23. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

24. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape

27. Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant

29. ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV

30. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

32. Divergence of Delta and Beta Variants and SARS-CoV-2 Evolved in Advanced HIV Disease into Two Serological Phenotypes

33. A principle‐based approach to justify the use of HIV self‐testing in South Africa.

34. Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection

35. Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like Particles

38. V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity

39. HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies

40. Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

42. Comparative Neutralization Sensitivity of Indian and South African HIV-1 Clade C Viruses to Plasma Antibodies from Chronically Infected Indian Donors

44. Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection

45. Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop

46. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera, regardless of the infecting variant

47. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity

48. Comparative Neutralization Sensitivity of Indian and South African HIV-1 Clade C Viruses to Plasma Antibodies from Chronically Infected Indian Donors.

49. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection.

50. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Catalog

Books, media, physical & digital resources